Stevanato Group S.p.A. (STVN) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong demand for high-value products, robust growth projections, and a resilient financial position despite FX headwinds and engineering delays. Management's optimistic guidance and strategic focus on capacity expansion and product innovation indicate positive sentiment. Although some uncertainties exist, particularly in the Engineering segment, the overall outlook supports a positive stock price movement.
Key Financial Performance
Third quarter revenue Increased by 9% year-over-year to $303.2 million, driven by a 14% increase in the BDS segment and offset by a 19% decline in the Engineering segment. The growth was primarily due to strong performance in the BDS segment and favorable timing of product shipments.
Revenue from high-value solutions Grew 47% year-over-year, representing 49% of total company revenue. This growth was driven by strong demand for Nexa Syringes and the recovery in EZ-fill vials.
Consolidated gross profit margin Increased by 240 basis points to 29.2% in the third quarter of 2025. This was due to a favorable mix of high-value solutions, financial improvements at Latin and Fishers facilities, and recovery in vial demand. However, it was partially offset by lower gross profit from the Engineering segment and currency translation impacts.
Operating profit margin Increased to 17.4%, and on an adjusted basis, rose 220 basis points to 18.5%, driven predominantly by an increase in gross profit.
Net profit Totaled $36.1 million with diluted EPS of $0.13. On an adjusted basis, net profit was $38.5 million, and adjusted diluted EPS increased 17% to $0.14.
Adjusted EBITDA Increased to $77.8 million, with the adjusted EBITDA margin improving by 280 basis points to 25.7%.
BDS segment revenue Increased by 14% to $266.7 million, driven by a record level of high-value solutions and recovery in EZ-fill vials. On a constant currency basis, BDS revenue grew by 17%.
Engineering segment revenue Decreased by 19% to $36.4 million, driven by lower revenue from glass conversion and assembly lines. Gross profit margin for the segment declined to 10.4% due to lower revenue and a higher proportion of complex legacy projects.
Cash and cash equivalents Stood at $113.3 million as of September 30, 2025, with net debt of $333 million.
Capital expenditures Totaled $54.9 million for the third quarter of 2025. Net cash from operating activities increased to $47.2 million, and free cash flow was approximately EUR 260,000 for the quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Nexa Syringes: Achieved 47% growth in high-value solutions, driven by Nexa syringes. Nexa platform is optimized for sensitive biologics and integrates seamlessly with auto-injectors.
EZ-fill Cartridges: Selected by a leading manufacturer for a GLP-1 biosimilar for type 2 diabetes, marking one of the first FDA-approved biosimilars in the U.S. Offers compatibility with pen injector systems, accelerating time to market.
Injectable Biologics: Strong demand for premium containment and delivery solutions for injectable biologics, driven by rising pharmaceutical innovation and self-administration trends.
U.S. Manufacturing Investments: Major pharmaceutical players are investing in U.S. manufacturing operations, driven by onshoring and regulatory upgrades.
Engineering Segment Optimization: Operational improvements made, but financial performance remains below expectations. Strengthening sales organization and refining commercial processes to improve order flow.
Fishers and Latina Facilities: Scaling commercial production for Nexa Syringes and EZ-fill cartridges. New clean room and injection molding machines being installed to support large device programs.
High-Value Solutions Focus: Strategic shift towards high-value solutions, now representing 49% of total revenue. Transitioning away from low-value syringes and diagnostics.
Sustainability Commitment: Awarded EcoVadis silver medal, placing in the top 15% globally for sustainability performance.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Foreign Currency and Tariff Costs: The company faced headwinds from foreign currency and certain tariff costs that were not mitigated, which tempered margins in the third quarter.
Engineering Segment Performance: The Engineering segment's financial performance is below expectations, with a 19% revenue decline and negative operating profit margin due to lower revenue from glass conversion and assembly lines, and a higher proportion of complex legacy projects.
Order Conversion in Engineering Segment: Converting the pipeline of new opportunities into orders has been slower than anticipated, impacting the segment's recovery and profitability.
Currency Translation Impact: Currency translation was worse than anticipated, with an expected impact of $15 million to $16 million for the full year, higher than the prior range of $12 million to $15 million.
Margin Dilution at New Facilities: The Fishers and Latina facilities are currently margin dilutive, though expected to improve as they scale up operations.
Pending Customer Validations: Customer validations for new vial lines and contract manufacturing activities are expected to begin in mid-2026, delaying revenue realization.
Regulatory and Quality Standards: Customers are upgrading technology to meet higher quality standards and stringent regulations, such as Annex 1, which may require additional investments and adjustments.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for Fiscal 2025: The company reiterates its fiscal 2025 revenue guidance in the range of $1.16 billion to $1.19 billion.
Adjusted EBITDA Guidance for Fiscal 2025: Adjusted EBITDA is expected to range between $288.5 million and $301.8 million.
Adjusted Diluted EPS Guidance for Fiscal 2025: Adjusted diluted EPS is projected to be between $0.50 and $0.54.
High-Value Solutions Revenue Contribution: The revenue from high-value solutions is now expected to range between 43% and 44% of total revenue, an increase from the prior assumption of 40% to 42%.
Currency Translation Impact: The impact from currency translation is now expected to be approximately $15 million to $16 million, compared to the prior range of $12 million to $15 million.
Capital Investment Projects: The company is advancing its capital investment projects in Fishers and Latina. Syringe lines in Fishers are in various stages of ramp-up, with vial lines expected to begin customer validations in mid-2026. Commercial activities for contract manufacturing are expected to begin at the end of 2026 or early 2027. In Latina, commercial production for Nexa Syringes is scaling and will continue into 2026, with preparations underway for the next phase of EZ-fill cartridge production.
Engineering Segment Outlook: The company expects to see benefits from strengthening the sales organization and refining commercial processes in the coming quarters. Long-term demand for manufacturing technologies remains strong, supported by industry capacity expansion and investments in U.S. manufacturing operations.
Market Trends and Tailwinds: The company anticipates strong secular tailwinds from the growth in biologics, rising pharmaceutical innovation, and the increasing trend towards self-administration of medicine. Customers are investing in new capital projects, onshoring operations in the U.S., and upgrading technology to meet higher quality standards and stringent regulations.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you provide more details on the $10 million outperformance in the quarter and the mix?
A:The $10 million outperformance was due to an acceleration to accommodate customer supply chain needs, shifting sales expected in Q4 to Q3. This primarily involved high-value solutions, particularly high-performance syringes.
Q:What drove the strong growth in high-value solutions this quarter, and what is the trajectory for next year?
A:Strong demand for high-performance syringes like Nexa and Alba, recovery in sterile vials, and increased demand for ready-to-fill cartridges drove growth. The trajectory is robust, with high-value products expected to account for 43%-44% of company revenue.
Q:Can you update us on the margin improvement story for the Latina and Fishers plants?
A:Latina is nearing normalized gross profit margins but remains dilutive. Fishers is improving but not yet gross profit margin positive, with expectations to achieve this by the end of the year.
Q:What is the timeline for the Engineering segment to return to growth?
A:The Engineering segment is making operational progress, but order conversion is delayed due to customer hesitations and reevaluations. Growth is expected in the coming quarters, with a healthy pipeline and positive customer feedback.
Q:Can you elaborate on the biosimilar opportunity and its contribution to growth?
A:Biosimilars are expected to enlarge revenue as products go off-patent. Stevanato is engaged with originators and biosimilars, leveraging its EZ-fill high-value product platform, Nexa syringes, and ready-to-fill cartridges.
Q:How does the FX currency headwind and engineering slowdown impact the guidance for the year?
A:Despite a EUR 2 million FX headwind and slower engineering orders, high-value products are performing better, offsetting these challenges. Guidance remains unchanged.
Q:What are the utilization rates for Fishers and Latina, and when will they reach full capacity?
A:Fishers and Latina are ramping up capacity, with full potential expected by the end of 2028. Investments are ongoing to meet demand for high-value products.
Q:How is onshoring impacting demand?
A:Onshoring is driving interest in U.S. facilities, with customers reevaluating their manufacturing footprints and increasing capacity in the U.S., benefiting Stevanato's Fisher plant.
Q:Is the $10 million order pull-through from a single customer, and will it repeat in Q4?
A:No, it is not from a single customer. The $10 million pull-through is a one-time event and will not repeat in Q4.
Q:What is the outlook for the Engineering segment and its impact on BDS?
A:The Engineering segment is seeing delays in order confirmations due to customer footprint reevaluations. However, this is expected to create future opportunities for BDS and Fisher plants.
Q:What is the capacity outlook for high-value solutions, and can it support continued growth?
A:Capacity for high-value solutions is being expanded across multiple facilities, with several hundred million units of additional capacity planned through 2028 to meet growing demand.
Q:What is driving the recovery in vial orders?
A:Recovery in vial orders is driven by normalization of customer inventories and new molecule launches using EZ-fill vials.
Q:Is the shift in mix and demand for high-value solutions durable or transitory?
A:The shift is durable, driven by investments in high-value products and a strategic focus on integrated systems for customers.
Q:How will drug pricing agreements impact Stevanato?
A:Drug pricing agreements are expected to increase market volumes, benefiting Stevanato as a packaging supplier with long-term contracts.
Q:What is the status of inventory destocking for vials?
A:Inventory destocking is largely behind, with customers normalizing their inventories and a 12% year-over-year increase in vial revenue.
Q:What is the outlook for 2026 growth?
A:Positive trends in high-value solutions, ramping up of Fishers and Latina plants, and progress in engineering support a positive outlook for 2026, with detailed guidance to be provided next quarter.
Q:What are the assumptions behind the high-value solutions guidance for Q4?
A:Q4 guidance assumes 40%-41% revenue from high-value solutions, reflecting Q3 pull-forward and backlog.
Q:What is the outlook for contract manufacturing?
A:Contract manufacturing is expected to grow, with Fisher's facility ramping up for auto-injector production by 2026-2027.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific timeline for Engineering segment growth and provided vague responses about the impact of onshoring and drug pricing agreements on future demand.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ESG
EUR
Engineering segment
Financial Results
Nexa Syringes
assumption
capital investment
cartridge line
commitment
container
contract manufacturing
core drug
currency basis
currency tariff
currency translation
cycle
demand core
development
device
drug containment
expenditure cash
fill cartridge
headwind currency
injection
integrity
investment capacity
investment market
investment project
manufacturing activity
phase EZ
platform
product shipment
recovery demand
segment demand
segment margin
segment period
shipment BDS
solution improvement
tariff margin
timing product
use
STVN Transcript
Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call reveals a mixed outlook. While there are positive signs such as margin expansion, strong biologics growth, and strategic capacity investments, there are also concerns about slower order materialization in the Engineering segment, inflationary pressures, and a lack of clarity in management's responses. The lack of new partnerships or significant shareholder return plans, along with no clear guidance changes, suggests a neutral sentiment. Without market cap data, the prediction remains neutral, assuming average volatility.
Stevanato Group S.p.A. (STVN) Q4 2025 Earnings Call Transcript
Positive3-4
The company reported a strong financial performance with a 15% revenue increase, improved gross margins, and a 25% rise in free cash flow. Despite regulatory risks, the positive financial metrics and optimistic guidance on capital projects and market trends suggest a favorable outlook. No negative sentiment from the Q&A was noted. Given these factors, the stock price is likely to experience a positive movement in the short term.
Stevanato Group S.p.A. (STVN) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call reveals strong demand for high-value products, robust growth projections, and a resilient financial position despite FX headwinds and engineering delays. Management's optimistic guidance and strategic focus on capacity expansion and product innovation indicate positive sentiment. Although some uncertainties exist, particularly in the Engineering segment, the overall outlook supports a positive stock price movement.
STVN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
